Spherium Biomed announced on May 17, 2018 that it has obtained positive results with its new drug Mucomel® in a phase I/IIa clinical trial for the prevention and treatment of oral mucositis in patients of head and neck cancer treated with chemo and radiotherapy.
It has been shown that Mucomel® reduces the incidence of severe mucositis to almost half of patients. In addition, in patients who develop mucositis, its duration is shortened with a reduction considered clinically very relevant by physicians who have participated in the study.
Spherium reported that it is negotiating with international partners the co-development of the clinical phase III of the drug, which is expected to be available in the market by approximately 2022.
ABG IP is proud to have collaborated with Spherium Biomed in the IP protection of Mucomel® and other products in the companies’ pipeline.
